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ABSTRACT
Background and aims There has been little empirical evidence to show the ‘real-world’ impact of scaling-up
direct-acting anti-viral (DAA) treatment among people who inject drugs (PWID) on hepatitis C virus (HCV) viraemia at
a population level. We aimed to assess the population impact of rapid DAA scale-up to PWID delivered through
community services—including drug treatment, pharmacies, needle exchanges and prisons—in the Tayside region of
Scotland, compared with Greater Glasgow and Clyde (GGC) and the Rest of Scotland (RoS). Design, setting and
participants Natural experiment, evaluated using data from national biennial surveys of PWID and national clinical
data. Services providing injecting equipment (2010–18) and HCV treatment clinics (2017–18) across Scotland. A total
of 12 492 PWID who completed a questionnaire and provided a blood spot (tested for HCV-antibodies and RNA); 4105
individuals who initiated HCV treatment. Intervention and comparator, measurements The intervention was rapid
DAA scale-up among PWID, which occurred in Tayside. The comparator was GGC/RoS. Trends in HCV viraemia and
uptake of HCV therapy over time; sustained viral response (SVR) rates to therapy by region and treatment setting.
Findings Uptake of HCV therapy (last year) among PWID between 2013–14 and 2017–18 increased from 15 to
43% in Tayside, 6 to 16% in GGC and 11 to 23% in RoS. Between 2010 and 2017–18, the prevalence of HCV viraemia
(among antibody-positives) declined from 73 to 44% in Tayside, 67 to 58% in GGC and 64 to 55% in RoS. The decline in
viraemiawas greater in Tayside [2017–18 adjusted odds ratio (aOR) = 0.47, 95% confidence interval (CI) = 0.30–0.75, P
= 0.001] than elsewhere in Scotland (2017–18 aOR = 0.89, 95% CI = 0.74–1.07, P = 0.220) relative to the baseline of
2013–14 in RoS (including GGC). Per-protocol SVR rates among PWID treated in community sites did not differ from
those treated in hospital sites in Tayside (97.4 versus 100.0%, P = 0.099). Conclusions Scale-up of direct-acting anti-
viral treatment among people who inject drugs can be achieved through hepatitis C virus (HCV) testing and treatment
in community drug services while maintaining high sustained viral response rates and, in the Tayside region of Scotland,
has led to a substantial reduction in chronic HCV in the population.
Keywords Hepatitis C, Chronic, direct-acting anti-virals, Viremia, sustained viral response, prevalence, Substance
Abuse, Intravenous.
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INTRODUCTION
In many countries, people who inject drugs (PWID)
comprise the largest population of people infected with
hepatitis C virus (HCV), as well as the largest group at
ongoing risk of infection [1]. In recognition of viral
hepatitis as a global problem, the World Health Organiza-
tion (WHO) has set targets to eliminate HCV, including an
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80% reduction in HCV incidence by 2030 [2]. To achieve
this target, countries will need to provide optimal coverage
of harm reduction services (including needle and syringe
programmes and opioid agonist therapy), but will also need
to prioritize major scale-up (i.e. expansion) of HCV treat-
ment for PWID [3–6]. Uptake of HCV therapy among
PWID has been very limited until the recent introduction
of direct-acting anti-viral therapies (DAAs)—highly effec-
tive, tolerable and simple-to-administer therapies for the
treatment of HCV infection [7–9]. Further, there has been
little empirical evidence to show the ‘real-world’ impact of
scaling-up HCV DAA treatment among PWID on HCV
viraemia at a population level [10–12].
In the Tayside region of Scotland an evaluation of the
impact of major and rapid scale-up of DAAs among PWID
is under way, involving the provision of HCV testing and
treatment across the full range of community services
engaged with this population, including drug treatment,
pharmacies, needle exchanges and prisons [13]. The
scale-up in Tayside, compared to other areas of Scotland,
provides a unique opportunity to evaluate a natural
experiment of the scale-up of DAAs on HCV viraemia
prevalence in the PWID population.
Scotland is one of the few countries world-wide with
comprehensive national surveillance systems, including
large serial cross-sectional bio-behavioural surveys of
PWID to monitor HCV infection and an HCV clinical
database to monitor treatment outcomes [14,15]. Using
these data, we assess the early impact of DAA scale-up in
Tayside compared to other regions in Scotland. We aim
to test the hypothesis that rapid scale-up of DAAs in
community-based services translates into a decline in
HCV viraemia among a population of PWID, and to test
whether this rapid scale-up leads to any differences in
sustained viral response (SVR) rates to therapy. Specifically,
we examined: (i) the population-level prevalence of HCV
therapy uptake, HCV viraemia and treatment-induced
viral clearance among PWID over time and by region, (ii)
the change in uptake of HCV therapy, HCV viraemia and
treatment-induced viral clearance among PWID over time
and by region and (iii) SVR rates by region, treatment
setting and PWID status.
METHODS
The current study forms one component of the ‘Evaluating
the population impact of hepatitis C direct acting anti-viral
treatment as prevention for people who inject drugs
(EPIToPe)’ study, a mixed-methods evaluation of a natural
experiment of HCV ‘Treatment as Prevention’ (TasP)
among PWID [13]. The ‘intervention’ consists of the
scale-up of DAAs and expansion of care pathways in
National Health Service (NHS) Tayside (an administrative
health region in Scotland), with other sites in Scotland
acting as the ‘controls’: NHS Greater Glasgow and Clyde
(GGC) and the Rest of Scotland (RoS). NHS Tayside has an
estimated 2700 PWID, which compares to 10 000 and
17 300 in GGC and RoS, respectively [13,16,17]. Preva-
lence of antibodies to HCV among PWID in Tayside in
2017–18 was 56% compared to 68% in GGC and 48% in
RoS [14]. The scale-up in Tayside involves the treatment
of at least 500 PWID over a 2–3-year period beginning in
2017; mathematical modelling has indicated that this has
the potential to reduce the chronic HCV prevalence among
PWID in Tayside from approximately 30 to 10% or less. In
the rest of Scotland, financial considerations precluded
rapid scale-up of treatment beyond those eligible via the
fibrosis-based prioritization in place at the time.
The data analysed here relate to a time-point midway
through scale-up, when approximately 200 PWID
(i.e. 40% of the target) had been treated in community
settings in Tayside. This study therefore evaluates the early
impact of the DAA scale-up in Tayside. To address the aims
described in the Introduction two sources of data were
utilized, which are described further below and summa-
rized in Box 1.
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HCV = hepatitis C virus; DBS = dried blood spot; GGC = Greater Glasgow &
Clyde; HCV = hepatitis C virus; ITT = intention-to-treat; NHS = National
Health Service; PWID = people who inject drugs; RNA = ribonucleic acid;
RoS = Rest of Scotland; SVR = sustained viral response
Data sources
Needle exchange surveillance initiative (NESI)
NESI is a national bio-behavioural survey of PWID that has
been undertaken approximately bienially since 2008–09
and covers an estimated 10–15% of the active PWID
population in Scotland [14]. Recruitment takes place at
sites that provide sterile injecting equipment across
Scotland (some of which may also provide opioid agonist
therapy); sites are chosen to be broadly geographically
representative and approximately 100 sites are included
per sweep, representing approximately 50% of all sites that
provide injecting equipment in Scotland. Trained inter-
viewers facilitate the completion of a questionnaire and
take a blood spot sample from all consenting participants.
Dried blood spots (DBS) are tested for antibodies to HCV
and HCV RNA; methods have been described in detail pre-
viously [14,18]. Written informed consent was obtained
from each patient included in the study and the study
protocol conforms to the ethical guidelines of the 1975
Declaration of Helsinki as reflected in approval by the West
of Scotland Research Ethics Committee (reference 08/
S0709/46).
As part of EPIToPe, approximately 200 PWID had been
treated in community settings in Tayside during 2017. As
part of the NESI 2017–18 sweep, interviews in Tayside
were carried out in early 2018. Thus, four sweeps of NESI
(2010, 2011–12, 2013–14 and 2015–16) were under-
taken prior to, and one (2017–18) following, the early
scale-up of DAAs.
Clinical database
The national Hepatitis C Clinical Database records clinical
and epidemiological information on patients attending a
specialist clinic for management of HCV infection and
covers 17 of the 18 clinics in Scotland (consisting of clinics
in hospitals, as well as nurse-led clinics in prisons and
community settings) [15]. We extracted data (age, sex
assigned at birth, injecting status, treatment dates, SVR
achievement, treatment setting and clinic) regarding
patients who commenced therapy between January 2017
and December 2018. Data were complete to 31 March
2019, so patients who commenced treatment at the
end of December 2018 had sufficient time to complete
treatment and have a follow-up SVR test.
Measurements
NESI
Based on the results of DBS testing, participants were
categorized as HCV antibody-positive or -negative. Anti-
body positives were further classified as viraemic (HCV
HCVamong people who inject drugs 3
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antibody-positive and HCV RNA-positive) or cleared
(HCV antibody-positive and HCV RNA-negative). In the
latest three surveys (2013–14, 2015–16 and
2017–18), participants were asked if they had com-
menced drug therapy for their HCV infection ever or
in the last year. Participants were further categorized
into the groups indicated in Box 2 by combining their
HCV infection status from their DBS test with their
self-reported uptake of therapy. Those with cleared infec-
tion who reported receiving HCV therapy in the past
(i.e. group A in Box 2) were defined as having ‘treat-
ment-induced viral clearance’.
In order to generate appropriate denominators for
HCV therapy uptake, we created definitions of individ-
uals who were ‘eligible for therapy’. The denominator
for those who had ever received therapy consisted of
those with viraemia (i.e. groups B and D in Box 2) plus
those who had cleared infection with evidence of
therapy (i.e. group A). The denominator for therapy
uptake in the last year consisted of those with viraemia
(i.e. groups F and H in Box 2) plus those who had
cleared infection with evidence of therapy in the last
year (i.e. group E).
Box 2. Classification of respondents into groups based on HCV
antibody/RNA status combined with self-reported history of HCV




















































Includes those who said they had not received treatment, as well as those
who were unaware of their hepatitis C virus (HCV) infection.
Clinical database
An SVR was defined as testing polymerase chain reaction
(PCR)-negative for HCV RNA at either 24 weeks
(pre-2014) or 12weeks (2014 onwards) following comple-
tion of therapy, according to clinical guidelines [19]. The
time-period is from the confirmed end of treatment (rather
than the expected end of treatment) if a patient prema-
turely discontinues. Only patients who had a documented
SVR at 24+ weeks (pre-2014) or 12+ weeks (2014
onwards) were considered to have a SVR. Intention-to-
treat (ITT) SVR rates were calculated as the number of pa-
tients who achieved SVR as a proportion of the number of
patients who commenced treatment. Per-protocol SVR
rates were calculated as the number of patients achieving
SVR as a proportion of the number of patients with an
SVR outcome recorded (i.e. excluding unknown results).
Statistical analysis
To describe the NESI participants, initial analyses looked at
demographic and behavioural variables, by survey year
and region: categorical variables were expressed as
numbers and percentages, whereas continuous variables
were presented as means or medians. To test for differences
across surveys, χ2 tests were performed for categorical var-
iables and Wilk’s lambda was calculated for continuous
variables.
The main statistical analyses undertaken are described
below under headings that relate to the three aims
described in the introduction.
Population-level prevalence of uptake of HCV therapy, HCV
viraemia and treatment-induced viral clearance (NESI data)
First, multiple imputation by chained equations (MICE)
was applied to the NESI data to impute missing HCV
antibody and HCV RNA results [20]. Missing data were as-
sumed to be missing-at-random (MAR). This assumption,
while not testable, was deemed plausible as there was no
reason to believe that there was any systematic
relationship between the absence of HCV antibody or
HCV RNA measurement and the missing value. Survey
year, region and time since onset of injecting were used
as predictors in the imputationmodel and 20 imputed data
sets were generated. Sensitivity analyses were performed
by comparing the results from MICE to results generated
from complete case analyses.
Where survey years were presented separately, NESI
respondents who had participated more than once within
a given survey year were identified (on the basis of initials,
sex assigned at birth, date of birth and NHS Board of re-
cruitment) and only their first interview/DBS was included
in the analysis (when pooling data across the surveys,
4 Norah E. Palmateer et al.
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participants who had participated multiple times across
survey years were considered: see multi-level logistic
regression).
The proportions of respondents in NESI who reported
ever/last year uptake of therapy with viraemia and with
treatment-induced clearancewere compared across survey
sweeps and NHS Board regions (Tayside/GGC/RoS). GGC
was presented separately because it is the largest
NHS board in Scotland (representing approximately 33%
of individuals with problem drug use in Scotland
and 40% of all NESI respondents in the included survey
years) [17].
Additionally, the setting where HCV therapy was initi-
ated among respondents in the2017–18 surveywas exam-
ined and a χ2 test was performed to test for a difference in
the proportion reporting community-initiated therapy
by region.
Associations of region and survey year with uptake of HCV
therapy, HCV viraemia and treatment-induced viral clearance
(NESI data)
We used logistic regression to examine the association
between the main predictors region and survey year
and the outcomes uptake of therapy (in the last year),
HCV viraemia (among antibody-positives) and treat-
ment-induced viral clearance (among antibody-positives)
in the NESI data collected from 2013–14 to 2017–18
(the models were restricted to these years because these
were the only surveys in which the HCV treatment ques-
tions were asked). GGC was combined with RoS in these
analyses to simplify the analysis of interactions between
region and year. Univariable models were constructed
for each predictor and outcome, followed by multivariable
models also adjusted for sex (assigned at birth), age, time
since onset of injecting, homelessness in the last 6 months
(yes/no), receipt of methadone in the last 6 months (yes/
no) and imprisonment in the last year (yes/no). Multivar-
iable models were fitted with interactions between survey
year and region and a likelihood ratio test (LRT)
was conducted to test for evidence of the interaction.
A multi-level regression modelling was used to take
clustering and non-independence of observations
among individuals into account, given that some
individuals had participated more than once across
the surveys (identified on the basis of initials, sex
(assigned at birth), date of birth and NHS Board of
recruitment).
SVR rates by region, treatment setting and PWID status
(clinical database)
Where individuals had multiple courses of treatment, the
SVR relating to the treatment episode with themost recent
completion date was used in the analysis. ITT and
per-protocol SVR rates were calculated by PWID
status, region (Tayside/GGC/RoS) and treatment setting
(hospital/prison/community).
Analyses were undertaken in Stata version 13.1 [21].
Graphs were produced in Excel 2016 and R version 3.5.1
[22,23]. The analysis was not pre-registered on a publicly
available platform, and therefore the results should be con-
sidered exploratory.
Role of the funding source
The funders had no role in the study design, data collec-
tion, data analysis, data interpretation, writing of the
report or the decision to submit for publication.
RESULTS
Atotalof12 492PWIDwhoparticipated in theNESI survey
and4105 individualswho initiatedHCV treatmentwere in-
cluded in this study.A further breakdownof the sample sizes
that were included in the different analyses is given in
Fig. 1a,b. An overview of the NESI samples recruited in
Tayside,GGCandRoSarepresented in theSupporting infor-
mation, Tables S1–S3, respectively. The prevalence of HCV
antibodies in Tayside (n = 818), GGC (n = 5105) and RoS
(n = 6358) ranged between 41–56, 63–69 and 44–52%,
respectively, between 2010 and 2017–18. Approximately
70–80% of the sample were male, and this was consistent
across the surveys and regions. Average age and time since
onset of injecting increased across the surveys in all
regions, suggestive of an ageing cohort effect. Excessive al-
cohol consumption was generally ower in Tayside com-
pared with GGC and RoS (ranging from 10 to 19, 23 to 30
and 19 to 30%, respectively). Cocaine injection in the last
6 months was also generally lower in Tayside and showed
evidence of an increase across the surveys in all regions
(from4 to14% inTayside, from16 to50% inGGCand from
7 to 19% in RoS).
Population-level prevalence of uptake of HCV therapy, HCV
viraemia and treatment-induced viral clearance (NESI data)
In Scotland overall, the proportion of those who said they
had ever received therapy or received therapy in the last
year increased from 19% (167 of 863) and 9% (72 of
800) in 2013–14 to 38% (301 of 785) and 21% (144 of
680), respectively, in 2017–18 (Table 1). In Tayside, uptake
of therapy in the last year increased from 15% (12 of 81) to
43% (26 of 61) between 2013–14 and 2017–18, com-
pared with 6% (22 of 378) to 16% (50 of 322) in GGC
and 11% (38 or 341) to 23% (68 of 297) in RoS.
Sensitivity analyses comparing the results from data
imputation to results generated from complete case
analyses are presented in the Supporting information,
Table S4. Results were robust to these changes. Between
HCVamong people who inject drugs 5
© 2021 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction
Figure 1 (a) Number of participants included in the analysis of population-level prevalence of uptake of hepatitis C virus (HCV) therapy, HCV
viraemia and treatment-induced viral clearance and the analysis of associations of region and survey year with uptake of HCV therapy, HCV viraemia
and treatment-induced viral clearance (data from the Needle Exchange Surveillance Initiative/NESI). (b) Participants included in the analysis of
sustained viral response (SVR) rates (data from the Scottish Hepatitis C Clinical Database)
6 Norah E. Palmateer et al.
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2010 and 2017–18, the prevalence of HCV viraemia in
Tayside decreased from 30% [95% confidence interval
(CI) = 24–36%] in 2010 to 24% (95% CI = 18–30%) in
2017–18 among all respondents and from 73% (95%
CI = 64–82%) to 44% (95% CI = 34–55%) among anti-
body-positives (Table 1 and Fig. 2). The latter compares
to declines from 67% (95% CI = 64–70%) to 58% (95%
CI = 54–63%) and 64% (95% CI = 61–68%) to 55%
(95% CI = 50–59%) among antibody-positives in GGC
and RoS, respectively.
The prevalence of treatment-induced clearance
(among antibody-positives) increased in Tayside from
16% (95% CI = 9–23%) to 40% (95% CI = 30–49%),
in comparison to 5% (95% CI = 3–6%) to 14% (95%
CI = 11–17%) in GGC and 10% (95% CI = 8–13%)
to 22% (95% CI = 18–25%) in RoS.
Figure 3 displays the setting where HCV therapy was
initiated among respondents in the 2017–18 survey. A
much larger proportion of respondents (74%, 62 of 84)
in Tayside reported starting treatment in the community,
compared with GGC (11%, 15 of 137) and RoS (27%, 52
of 190) (χ2 = 108.86, P < 0.001).
Associations of region and survey year with uptake of HCV
therapy, HCV viraemia and treatment-induced viral clearance
(NESI data)
PWID recruited in Tayside were more likely to have
reported uptake of therapy, after adjustment for survey
Figure 2 Prevalence of viraemic and cleared HCV infection among people who inject drugs attending injection equipment provision services across
Scotland, 2013 to 2018. Figures present (a) all respondents and (b) HCV antibody-positives only (data from the Needle Exchange Surveillance
Initiative/NESI). Ab = antibody; GGC = Greater Glasgow and Clyde; HCV = hepatitis C virus; RNA = ribonucleic acid
8 Norah E. Palmateer et al.
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Table 2 Logistic regression analyses of (a) uptake of therapy in the last year, (b) HCV viraemia (among HCV antibody-positives) and (c)
treatment-induced viral clearance (among HCV antibody-positives), by region and survey year, among people who inject drugs




aOR (95% CI) P-value
Uptake of therapy (in last year)b Rest of Scotland (including GGC) (n = 2680)
2013–14 1
2015–16 0.65 (0.44–0.97) 0.033
2017–18 2.35 (1.67–3.31) <0.001
Tayside 2013–14 2.12 (1.10–4.08) 0.025
2015–16 2.87 (1.67–4.92) <0.001
2017–18 5.19 (2.87–9.37) <0.001
HCV viraemia (among HCVantibody-positives) Rest of Scotland (including GGC) (n = 3681)
2013–14 1
2015–16 1.50 (1.27–1.77) <0.001
2017–18 0.89 (0.74–1.07) 0.220
Tayside 2013–14 0.96 (0.64–1.44) 0.853
2015–16 0.57 (0.38–0.84) 0.005
2017–18 0.47 (0.30–0.75) 0.001
Treatment-induced viral clearance
(among HCVantibody-positives)
Rest of Scotland (including GGC) (n = 3681)
2013–14 1
2015–16 0.70 (0.51–0.96) 0.027
2017–18 2.49 (1.88–3.30) <0.001
Tayside 2013–14 2.46 (1.40–4.33) 0.002
2015–16 4.37 (2.60–7.35) <0.001
2017–18 4.12 (2.56–6.61) <0.001
aOR = adjusted odds ratio; CI = confidence interval; HCV = hepatitis C virus; GGC = Greater Glasgow and Clyde.
a
Adjusted odds ratios (aORs) derived from
multivariable models with interaction effects (see supporting information, Table S5 for univariable and main effects models). Multivariable models are also
adjusted for sex, age, time since onset of injecting, homelessness (last 6 months), receipt of methadone (last 6 months) and imprisonment (last year);
b
among therapy–eligible respondents; see Methods for definitions.
Figure 3 Site of initiation of most recent course of HCV therapy* among people who inject drugs attending injection equipment provision services
across Scotland, 2017–18 (data from the Needle Exchange Surveillance Initiative/NESI). GGC = Greater Glasgow and Clyde; GP = general practice;
HCV = hepatitis C virus. *Among those who had ever received HCV therapy; †includes needle exchanges, drug treatment sites, community health
centres and at an individual’s home
HCVamong people who inject drugs 9
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year and other variables [Supporting information,
Table S5: adjusted odds ratio (aOR) = 3.13, 95%
CI = 2.22–4.41]. While there was insufficient evidence
for an interaction between year and region (likelihood ratio
test/LRT, P = 0.112), stratified analyses were suggestive of
a larger increase in uptake of therapy in Tayside
(aOR = 5.19, 95% CI = 2.87–9.37) compared with RoS
(aOR = 2.35, 95% CI = 1.67–3.31), where the baseline
for comparison was 2013–14 RoS (Table 2).
After adjustment, respondents in Tayside had lower
odds of viraemia (aOR = 0.66, 95% CI = 0.52–0.84) com-
pared with those in the rest of Scotland, with evidence of
an interaction between region and year (LRT, P = 0.034),
indicating that there was a larger reduction in HCV
viraemia in Tayside (aOR = 0.47, 95% CI =0.30–0.75)
compared with RoS (aOR = 0.89, 95% CI = 0.74–1.07),
when compared to RoS 2013–14 (Table 2 and Supporting
information, Table S5).
After adjustment, respondents in Tayside were more
likely to have treatment-induced clearance (Supporting
information, Table S5: aOR = 3.57, 95% CI = 2.65–4.81)
compared with those in the rest of Scotland. There was
insufficient evidence of an interaction between region
and year (LRT, P = 0.254), but some evidence of a larger
increase in treatment-induced clearance in Tayside
(aOR = 4.12, 95% CI = 2.56–6.61) compared with RoS
(aOR = 2.49, 95% CI = 1.88–3.30) (Table 2).
SVR rates by region, treatment setting and PWID status
(clinical database)
There was a difference of approximately 6–8 percentage
points in ITT rates between PWID and non-PWID in GGC
(74 versus 81%, P = 0.007), RoS (66 versus 72%,
P = 0.008) and Tayside (78 versus 86%, P = 0.119)
(Table 3, Fig. 4, Supporting information, Fig. S1). In all
Scottish regions, per-protocol SVR rates did not differ sig-
nificantly between PWID and non-PWID. There was evi-
dence that ITT SVR rates were lower in community
settings compared with hospital settings in GGC (70 versus
80%, P < 0.001), RoS (65 versus 72%, P = 0.01) and
Tayside (78 versus 85%, P = 0.121). Per-protocol SVR
rates did not differ significantly across treatment settings
in any Scottish regions.
DISCUSSION
In this study, we found that rapid scale-up of DAAs
among PWID in community settings in Tayside led to
a greater decline in the prevalence of viraemic infection
among PWID than elsewhere in Scotland. There was
also evidence that HCV viraemia declined, to a lesser
extent, in other sites in Scotland correlated with in-
creases in HCV treatment. Further, we found that the
increase in community treatment in Tayside was not as-
sociated with any reduction in SVR rates in per-protocol
analyses.
While numerous mathematical modelling studies have
examined the hypothetical impact of scaling-up HCV
therapy on chronic HCV prevalence, there has been little
empirical evidence to corroborate these models [11–13].
One study has examined the impact of DAAs on chronic
HCV prevalence at a subnational level (in prisons) [24].
Other ‘real-world’ evidence published focuses upon scal-
ing-up treatment and SVR, rather than impact at a popu-
lation level [25–27]. To our knowledge, only one other
study to date has used national data to examine the impact
of treatment scale-up among PWID on viraemic
prevalence at a population level. They found that treat-
ment uptake (ever) among Australian PWID increased
from 10 to 41%, and that viraemic prevalence decreased
from 43 to 25% overall, between 2015 and 2017 [10].
However, direct comparisons with Australia cannot be
drawn, given the different interventions: they evaluated
the impact (pre versus post) of the introduction of
completely unrestricted access to DAAs across the
country, whereas we evaluated an intervention (that had
been demonstrated in mathematical models to deliver
population-level change in HCV viraemia) involving
scale-up of DAAs in a specific PWID population, compared
with a natural control group, through delivery of therapy
across multiple community-based settings. Further, a limi-
tation recognized in the Australian study was the amount
of missing RNA results from DBS testing (44–60% of
antibody-positive samples across the 3 years of data),
whichmay have led to bias within their analysis, compared
in our study to 4–11% missing RNA results.
It is notable that treatment interventions had been
occurring in Tayside prior to EPIToPe, albeit to a much
lesser extent, with approximately 100 PWID treated with
interferon-based therapies during 2012–16 [28]. These
treatment interventions may account for the higher
uptake of therapy at ‘baseline’ (i.e. pre-EPIToPe scale-up)
in Tayside compared with other regions. However, while
these early interventions did not constitute ‘rapid’ scale-
up, they can nevertheless be considered as part of the pack-
age of treatment interventions delivered to PWID in
Tayside and their impact can be seen pre-2017–18. We
have demonstrated the impact of partial scale-up; future
sweeps of NESI will allow us to measure further progress
towards reducing viraemia to 10% or lower.
DAA scale-up is one of the key tools for countries to
achieve HCV elimination. In their strategy for elimination
of viral hepatitis, the WHO have set targets relating to
incidence of HCV infection, but not for prevalence
viraemia/chronic infection [2]. We believe that monitoring
impact on prevalence of viraemia is a necessity to evaluate
the direct, short-term impact of DAA scale-up, as any
10 Norah E. Palmateer et al.
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increase in recent therapy uptake would be directly
observable in viraemic prevalence. We acknowledge that
is nevertheless important, in the longer term, to monitor
incidence, as this can also impact upon viraemic preva-
lence. In particular, incidence of HCV re-infection is a key
consideration with regard to HCV elimination among
PWID: if population-level viremia is not rapidly reduced
to sufficiently low levels, then re-infections will cause a rise
in the HCV viraemic prevalence [29]. Future analyses ex-
amining the impact of full scale-up in Tayside will consider
both primary incident infections and re-infections.
We have also provided evidence that rapidly scaling-up
treatment to people through community drug services
(and who are therefore probably continuing to inject either
during and/or after therapy) does not compromise SVR
rates. Although the intention-to-treat SVR rates were
lower in community sites (compared with hospital) and
among PWID, this is probably a result of PWID not attend-
ing their appointment for confirmation of SVR and is there-
fore a reflection of lack of follow-up rather than lack of SVR
attainment [30]. The latter is corroborated by NESI data
from Tayside in 2017–18 which show that, of those who
said that they had been initiated on treatment in the last
year (who we can assume are a mixture of individuals
who did/did not return for a confirmatory SVR test), 96%
were PCR-negative (95% CI = 81–99%). Non-compliance
is nevertheless a concern, as there is evidence to
suggest poor health outcomes among non-compliant
individuals; however, they represent a small minority of
the patients who commence therapy [31]. Although the
DAAs are highly tolerable, easy to take/administer and in-
volve a much shorter course of treatment than the
interferon-based therapies, compliance can nevertheless
be challenging for individuals with complex personal and
social circumstances [30].
A major strength of our analysis is the ‘natural
experiment’ design, whereby Tayside represents the
‘intervention’ group and GGC/RoS are the ‘control’ group.
A further strength of our study is the data sources, which
are comprehensive and national: few countries are in a
position to be able to measure population-level changes
in HCV viraemia among PWID, NESI being one of only four
serial bio-behavioural studies of its kind internationally
[10,32,33]. However, we acknowledge several limitations.
First, we relied upon self-report for uptake of HCV therapy,
whichmay be subject to recall and social desirability biases.
Secondly, there is sampling variation between the serial
surveys and could be a potential reason for differences
between the survey sweeps. However, most sample charac-
teristics were relatively stable across the period examined
or followed expected trends—such as the increase in
cocaine injecting [34]. Thirdly, there were variations in
prevalence of HCV antibody in Tayside, which was
41–42% in 2010–12 and increased to 56% in 2013–14.
These changes may result from selection bias because, as
part of the intervention, treatment became available at
some of the needle exchange and drug treatment settings
where NESI recruitment takes place, potentially attracting
more hepatitis C-infected clientele, thereby artificially in-
creasing the prevalence [28,35]. To account for this issue,
we analysed and presented the viraemia data among HCV
antibody-positives, which removed any variation in overall
antibody prevalence (we have also presented the preva-
lence of viraemia among all respondents for comparison
Figure 4 Intention-to-treat/per-protocol SVR rates by region and treatment setting among patients attending specialist liver clinics in Scotland,
2017–18 (data from the Hepatitis C clinical database). GGC = Greater Glasgow and Clyde; SVR= sustained viral response
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purposes). We acknowledge that this selection bias could
also have affected the rates of treatment uptake and
viraemia itself for the same reasons. However, if we exam-
ine the distribution of settings where individuals initiated
treatment from the clinical database (which captures a
comprehensive picture of all those receiving treatment),
24, 9 and 67% of treatment initiations in Tayside in
2017–18 occurred in hospitals, prisons and community
settings, respectively. Comparing that to the distribution
obtained fromNESI respondents recruited in Tayside shows
that the oversampling from community settings, while not
insignificant, is not vast (with 11, 10 and 79% of treatment
initiations in 2017–18 in hospitals, prisons and commu-
nity settings, respectively). A fourth limitation of the study
relates to the assays used to detect HCVantibody and RNA
on DBS. The sensitivity and specificity of the antibody test
are 99 and 100%, respectively; the corresponding values
for the PCR test are 100 and 96% [36,37]. There is there-
fore a very small chance of false negatives or false positives
on both tests. We may have missed individuals who had
very recently been infected, given that antibody and RNA
levels may fall below the lower limits of detection during
this time [38]. However, these are likely to be very small
numbers and should therefore not affect our viraemic
prevalence estimates [18]. Finally, the incomplete treat-
ment data was a limitation and is reflected in the ITT
SVR rates as they include missing confirmatory tests.
In conclusion, we have demonstrated the feasibility and
effectiveness of an approach that involves HCV testing and
treatment in a range of community services engaged with
PWID in increasing HCV treatment uptake and thereby
reducing the prevalence of HCV viraemia. Our findings
provide compelling evidence for other countries to plan
their HCV elimination strategies.
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